US4582797A
(en)
*
|
1980-09-25 |
1986-04-15 |
The Salk Institute For Biological Studies |
Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
|
DE3105150A1
(de)
*
|
1981-02-12 |
1982-08-19 |
Dr. Eduard Fresenius, Chemisch-pharmazeutische Industrie KG, 6380 Bad Homburg |
Herstellung von anti-t-lymphozyten-globulin.
|
US4474893A
(en)
*
|
1981-07-01 |
1984-10-02 |
The University of Texas System Cancer Center |
Recombinant monoclonal antibodies
|
US4657852A
(en)
*
|
1982-04-02 |
1987-04-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for B cell typing of total human lymphocyte sample
|
US4471056A
(en)
*
|
1982-04-02 |
1984-09-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Method for HLA-DR typing of total human lymphocyte sample
|
US4511662A
(en)
*
|
1982-06-18 |
1985-04-16 |
Bio-Rad Laboratories, Inc. |
Simultaneous assay for T and B lymphocyte populations and subpopulations
|
US4443427A
(en)
*
|
1982-06-21 |
1984-04-17 |
Sidney Farber Cancer Institute, Inc. |
Monoclonal antibody
|
US4500637A
(en)
*
|
1982-07-19 |
1985-02-19 |
The United States Of America As Represented By The Department Of Health And Human Services |
Prevention of graft versus host disease following bone marrow transplantation
|
US4714613A
(en)
*
|
1982-09-30 |
1987-12-22 |
The Albert Einstein College Of Medicine Of Yeshiva University |
Method of suppressing cell growth by immunotherapy
|
US4550086A
(en)
*
|
1983-02-16 |
1985-10-29 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies that recognize human T cells
|
US4579827A
(en)
*
|
1983-03-11 |
1986-04-01 |
Sloan-Kettering Institute For Cancer Research |
Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
|
US4797475A
(en)
*
|
1983-05-20 |
1989-01-10 |
The Regents Of The University Of California |
Method and composition for isolating white cell elements
|
US4645738A
(en)
*
|
1983-09-30 |
1987-02-24 |
Memorial Sloan-Kettering Institute Cancer Center |
Method for differential diagnosis of T cell leukemias using monoclonal antibodies
|
US4468346A
(en)
*
|
1983-10-27 |
1984-08-28 |
The United States Of America As Represented By The Secretary Of Agriculture |
Monoclonal antibodies to porcine immunoglobulins
|
JPS60231699A
(ja)
*
|
1983-11-09 |
1985-11-18 |
Aichiken |
正常及び悪性ヒト造血器細胞に対するモノクローナル抗体
|
US4672044A
(en)
*
|
1984-08-24 |
1987-06-09 |
Scripps Clinic & Research Foundation |
Murine monoclonal antibody combining site to human C3b receptor (CR1)
|
US4661446A
(en)
*
|
1985-02-19 |
1987-04-28 |
Dana-Farber Cancer Institute, Inc. |
Monoclonal antibodies and method of immunizing therewith
|
US5431897A
(en)
*
|
1985-04-19 |
1995-07-11 |
Sloan-Kettering Institute For Cancer Research |
Method of imaging colorectal carcinoma lesion and composition for use therein
|
US5091178A
(en)
*
|
1986-02-21 |
1992-02-25 |
Oncogen |
Tumor therapy with biologically active anti-tumor antibodies
|
US4970299A
(en)
*
|
1986-07-03 |
1990-11-13 |
Sloan-Kettering Institute For Cancer Research |
Monoclonal antibodies selective for prostate cancer
|
US5158885A
(en)
*
|
1987-10-16 |
1992-10-27 |
Biomedical Systems Ltd |
Mouse monoclonal antibodies raised to the t-cell line hsb-2 and t-cell chronic lymphocytic leukemia (t-cll) cells react with normal human t and b lymphocytes and monocytes
|
US5601819A
(en)
*
|
1988-08-11 |
1997-02-11 |
The General Hospital Corporation |
Bispecific antibodies for selective immune regulation and for selective immune cell binding
|
IL92382A
(en)
*
|
1988-11-23 |
1994-12-29 |
Univ Michigan |
Use of a ligand specific for CD28 in the manufacture of medicament
|
JPH0291833U
(fr)
*
|
1988-12-29 |
1990-07-20 |
|
|
JPH0277212U
(fr)
*
|
1989-01-25 |
1990-06-13 |
|
|
US6406696B1
(en)
|
1989-10-27 |
2002-06-18 |
Tolerance Therapeutics, Inc. |
Methods of stimulating the immune system with anti-CD3 antibodies
|
DE69032484D1
(de)
*
|
1989-10-27 |
1998-08-20 |
Arch Dev Corp |
Zusammensetzungen und deren verwendung zur förderung der immunopotentiation
|
JPH0420550U
(fr)
*
|
1990-06-11 |
1992-02-20 |
|
|
US5444155A
(en)
*
|
1991-09-10 |
1995-08-22 |
The Scripps Research Institute |
Molecules with antibody combining sites that induce asymmetry
|
US5250426A
(en)
*
|
1991-10-22 |
1993-10-05 |
The Scripps Research Institute |
Molecules with antibody combining sites that induce asymmetry
|
US6491916B1
(en)
|
1994-06-01 |
2002-12-10 |
Tolerance Therapeutics, Inc. |
Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
|
US20030108548A1
(en)
*
|
1993-06-01 |
2003-06-12 |
Bluestone Jeffrey A. |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
WO1997023237A1
(fr)
|
1995-12-22 |
1997-07-03 |
Immunomedics, Inc. |
Utilisation d'immunoconjugues pour accroitre l'efficacite des vaccins multietapes stimulant les reactions immunitaires en cascade
|
EP2065396A1
(fr)
|
1996-08-30 |
2009-06-03 |
Human Genome Sciences, Inc. |
Interleukine-19
|
WO1999026658A1
(fr)
|
1997-11-24 |
1999-06-03 |
Wong Johnson T |
Procedes de traitement des infections par le vih ou autres infections utilisant un activateur de lymphocytes t ou un activateur viral et therapie d'association anti-retrovirale
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
US7678836B2
(en)
*
|
1999-11-04 |
2010-03-16 |
Fxs Ventures, Llc |
Method for rendering a contact lens wettable
|
US8557868B2
(en)
*
|
2000-11-04 |
2013-10-15 |
Fxs Ventures, Llc |
Ophthalmic and contact lens solutions using low molecular weight amines
|
US9492582B2
(en)
*
|
2000-11-08 |
2016-11-15 |
Fxs Ventures, Llc |
Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
|
US9308264B2
(en)
|
2000-11-08 |
2016-04-12 |
Fxs Ventures, Llc |
Ophthalmic contact lens solutions containing forms of vitamin B
|
US20060127496A1
(en)
*
|
2000-11-08 |
2006-06-15 |
Bioconcept Laboratories |
L-histidine in ophthalmic solutions
|
US20070110782A1
(en)
*
|
2000-11-08 |
2007-05-17 |
Fxs Ventures, Llc |
L-histidine in ophthalmic solutions
|
CA2428985C
(fr)
|
2000-11-08 |
2011-05-24 |
Bio-Concept Laboratories |
Solutions ophtalmiques ameliorees et solutions pour lentilles de contact contenant des saccharides simples utilises comme activateurs de conservation
|
US20060148665A1
(en)
*
|
2000-11-08 |
2006-07-06 |
Bioconcept Laboratories |
Ophthalmic and contact lens solutions containing forms of vitamin b
|
US20070104744A1
(en)
*
|
2000-11-08 |
2007-05-10 |
Fxs Ventures, Llc |
Ophthalmic and contact lens solutions containing forms of vitamin b
|
PT1337262E
(pt)
*
|
2000-11-08 |
2008-10-24 |
Fxs Ventures Llc |
Soluções melhoradas para oftalmologia e para lentes de contacto com uma fonte de peróxido e um conservante catiónico polimérico
|
US7939501B2
(en)
*
|
2003-04-15 |
2011-05-10 |
Smith Francis X |
Ophthalmic and contact lens solutions containing peptides as preservative
|
BRPI0415457A
(pt)
*
|
2003-10-16 |
2006-12-05 |
Micromet Ag |
constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
|
DK1687066T3
(da)
|
2003-11-14 |
2012-11-26 |
Brigham & Womens Hospital |
Fremgangsmåder til immunmodulering
|
US8663634B2
(en)
*
|
2005-07-11 |
2014-03-04 |
Macrogenics, Inc. |
Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
|
SG10201504662WA
(en)
*
|
2006-06-14 |
2015-07-30 |
Macrogenics Inc |
Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity
|
AU2007337082A1
(en)
*
|
2006-12-21 |
2008-07-03 |
Macrogenics Inc. |
Methods for the treatment of LADA and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity
|
PL3042957T3
(pl)
|
2009-07-17 |
2018-03-30 |
Bioatla Llc |
Jednoczesna, zintegrowana selekcja i ewolucja wydajności ludzkiego białka i wyrażanie w gospodarzu do wytwarzania
|
BR112012027531A2
(pt)
|
2010-04-29 |
2017-08-08 |
Hadasit Medical Res Service And Development Co Ltd |
método de tratamento e/ou prevenção de progresso e/ou atraso de desenvolvimento de hepatite em um indivíduo, uso de uma molécula imunológica anti-cd3 e composição farmacêutica
|
SG10201902596TA
(en)
|
2010-07-16 |
2019-04-29 |
Bioatla Llc |
Novel methods of protein evolution
|
JP2014500879A
(ja)
|
2010-11-16 |
2014-01-16 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Bcma発現に相関性を有する疾患を治療する因子及び方法
|
ES2609439T3
(es)
|
2010-12-31 |
2017-04-20 |
Bioatla Llc |
Humanización rápida de anticuerpos
|
WO2012092376A2
(fr)
|
2010-12-31 |
2012-07-05 |
Short Jay M |
Génération d'anticorps monoclonaux entiers
|
CN104583239B
(zh)
|
2012-05-10 |
2018-09-18 |
生物蛋白有限公司 |
多特异单克隆抗体
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
AU2015204840B2
(en)
|
2014-01-07 |
2020-01-30 |
Bioatla, Llc |
Proteins targeting orthologs
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
IL280738B
(en)
|
2014-04-16 |
2022-07-01 |
Juno Therapeutics Gmbh |
Methods, kits and device for increasing cell populations
|
CN107108738A
(zh)
|
2014-07-25 |
2017-08-29 |
西托姆克斯治疗公司 |
抗cd3抗体、可活化抗cd3抗体、多特异性抗cd3抗体、多特异性可活化抗cd3抗体及其使用方法
|
WO2016059220A1
(fr)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Agents d'activation du tcr à utiliser dans le traitement de la lla-t
|
PL3221359T3
(pl)
|
2014-11-17 |
2020-11-16 |
Regeneron Pharmaceuticals, Inc. |
Sposoby leczenia nowotworów przy użyciu dwuswoistego przeciwciała CD3XCD20
|
UA126269C2
(uk)
|
2015-01-23 |
2022-09-14 |
Санофі |
АНТИТІЛОПОДІБНИЙ ЗВ’ЯЗУВАЛЬНИЙ БІЛОК, ЯКИЙ СПЕЦИФІЧНО ЗВ’ЯЗУЄТЬСЯ З ПОЗАКЛІТИННИМ ДОМЕНОМ CD3<font face="Symbol">e</font> ЛЮДИНИ І З CD123<font face="Symbol">e</font>
|
WO2016166568A1
(fr)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil permettant d'augmenter une population de cellules
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
BR112018008111A2
(pt)
|
2015-10-22 |
2018-11-06 |
Juno Therapeutics Gmbh |
métodos, kits, agentes e aparelhos para transdução
|
EP3371311B1
(fr)
|
2015-11-06 |
2021-07-21 |
Orionis Biosciences BV |
Protéines chimères bifonctionnelles et leurs utilisations
|
WO2017134305A1
(fr)
|
2016-02-05 |
2017-08-10 |
Orionis Biosciences Nv |
Agents de signalisation bispécifiques et leurs utilisations
|
TWI790206B
(zh)
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
|
JP2020505955A
(ja)
|
2017-02-06 |
2020-02-27 |
オリオンズ バイオサイエンス インコーポレイテッド |
標的化改変型インターフェロン及びその使用
|
MA49288A
(fr)
|
2017-04-27 |
2020-03-04 |
Juno Therapeutics Gmbh |
Reactifs particulaires oligomères et leurs méthodes d'utilisation
|
KR20210098450A
(ko)
|
2018-10-31 |
2021-08-10 |
주노 테라퓨틱스 게엠베하 |
세포의 선택 및 자극을 위한 방법 및 이를 위한 장치
|
BR112021008738A2
(pt)
|
2018-11-06 |
2021-11-03 |
Juno Therapeutics Inc |
Processo para produzir células t geneticamente construídas
|
EP4037774A1
(fr)
|
2019-10-02 |
2022-08-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Méthodes de traitement de la leucémie à cellules t de l'adulte
|
AU2020377043A1
(en)
|
2019-10-30 |
2022-06-02 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
MX2022009832A
(es)
|
2020-02-12 |
2023-02-14 |
Juno Therapeutics Inc |
Composiciones de celulas t de receptor de antigeno quimerico dirigido a cd19 y usos de las mismas.
|
US20230087953A1
(en)
|
2020-02-12 |
2023-03-23 |
Juno Therapeutics, Inc. |
Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof
|
JP2023517611A
(ja)
|
2020-03-10 |
2023-04-26 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
Il-6/il-6r抗体の組成物及びその使用方法
|
WO2021231661A2
(fr)
|
2020-05-13 |
2021-11-18 |
Juno Therapeutics, Inc. |
Procédé de production de lots de cellules donneuses exprimant un récepteur recombinant
|
CA3175784A1
(fr)
|
2020-06-17 |
2021-12-23 |
Kunwar Shailubhai |
Compositions et procedes pour augmenter les therapies par lymphocytes t a recepteur d'antigene chimerique (car)
|
JP2023535792A
(ja)
|
2020-07-30 |
2023-08-21 |
ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー |
コロナウイルス治療のための抗cd3抗体
|
EP4323404A1
(fr)
|
2021-04-16 |
2024-02-21 |
Tiziana Life Sciences PLC |
Administration sous-cutanée d'anticorps pour le traitement d'une maladie
|
WO2022234009A2
(fr)
|
2021-05-06 |
2022-11-10 |
Juno Therapeutics Gmbh |
Méthodes de stimulation et de transduction de lymphocytes t
|
WO2023064942A1
(fr)
|
2021-10-14 |
2023-04-20 |
Tiziana Life Sciences Plc |
Méthodes d'inhibition de l'activation microgliale
|
WO2023133595A2
(fr)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
|
WO2023147331A1
(fr)
|
2022-01-26 |
2023-08-03 |
Mabswitch Inc. |
Molécule bispécifique ayant une affinité accordable vis-à-vis d'un antigène ciblé
|
WO2023147510A1
(fr)
|
2022-01-28 |
2023-08-03 |
Juno Therapeutics, Inc. |
Réseaux de chromatographie et méthodes et kits associés
|
WO2023150518A1
(fr)
|
2022-02-01 |
2023-08-10 |
Sana Biotechnology, Inc. |
Vecteurs lentiviraux ciblant cd3 et leurs utilisations
|
WO2023193015A1
(fr)
|
2022-04-01 |
2023-10-05 |
Sana Biotechnology, Inc. |
Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral
|
WO2023213969A1
(fr)
|
2022-05-05 |
2023-11-09 |
Juno Therapeutics Gmbh |
Protéine de liaison virale et réactifs, articles et méthodes d'utilisation associés
|
WO2023230581A1
(fr)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Procédés de fabrication de thérapies par lymphocytes t
|
WO2024044655A1
(fr)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Administration de protéines hétérologues
|
WO2024100604A1
(fr)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Procédés de fabrication de cellules immunitaires modifiées
|
WO2024119157A1
(fr)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Particules lipidiques avec cofusogènes et leurs procédés de production et d'utilisation
|
WO2024124132A1
(fr)
|
2022-12-09 |
2024-06-13 |
Juno Therapeutics, Inc. |
Procédés d'apprentissage automatique pour prédire un phénotype cellulaire au moyen d'une imagerie holographique
|